Unknown

Dataset Information

0

Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors.


ABSTRACT: In this work, design, synthesis, and screening of thiophene carboxamides 4-13 and 16-23 as dual vascular endothelial growth factor receptors (VEGFRs) and mitotic inhibitors was reported. All compounds were screened against two gastrointestinal solid cancer cells, HepG-2 and HCT-116 cell lines. The most active cytotoxic derivatives 5 and 21 displayed 2.3- and 1.7-fold higher cytotoxicity than Sorafenib against HepG-2 cells. Cell cycle and apoptosis analyses for compounds 5 and 21 showed cells accumulation in the sub-G1 phase, and cell cycle arrest at G2/M phase. The apoptotic inducing activities of compounds 5 and 21were correlated to the elevation of p53, increase in Bax/Bcl-2 ratio, and increase in caspase-3/7.Compounds 5 and 21 showed potent inhibition againstVEGFR-2 (IC50?=?0.59 and 1.29??M) and ?-tubulin polymerization (73% and 86% inhibition at their IC50 values).Molecular docking was performed with VEGFR-2 and tubulin binding sites to explain the displayed inhibitory activities.

SUBMITTER: AbdElhameid MK 

PROVIDER: S-EPMC6136361 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Design, synthesis, and screening of ortho-amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors.

AbdElhameid Mohammed K MK   Labib Madlen B MB   Negmeldin Ahmed T AT   Al-Shorbagy Muhammad M   Mohammed Manal R MR  

Journal of enzyme inhibition and medicinal chemistry 20181201 1


In this work, design, synthesis, and screening of thiophene carboxamides 4-13 and 16-23 as dual vascular endothelial growth factor receptors (VEGFRs) and mitotic inhibitors was reported. All compounds were screened against two gastrointestinal solid cancer cells, HepG-2 and HCT-116 cell lines. The most active cytotoxic derivatives 5 and 21 displayed 2.3- and 1.7-fold higher cytotoxicity than Sorafenib against HepG-2 cells. Cell cycle and apoptosis analyses for compounds 5 and 21 showed cells acc  ...[more]

Similar Datasets

| S-EPMC3089059 | biostudies-literature
| S-EPMC4170804 | biostudies-literature
| S-EPMC8348251 | biostudies-literature
| S-EPMC6887723 | biostudies-literature
| S-EPMC5957078 | biostudies-literature
| S-EPMC3102432 | biostudies-literature
| S-EPMC6983134 | biostudies-literature
| S-EPMC9268560 | biostudies-literature
| S-EPMC5602572 | biostudies-literature
| S-EPMC3479662 | biostudies-literature